New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Touijer accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MPH, Harvard School of Public Health; MD, Universite Hassan II
Urology - Centre Hospitalier Universitaire; Family Medicine - University of Kansas Medical Center; General Surgery - University of Kansas Medical Center; Urology - University of Arkansas for Medical Sciences
Urologic Oncology - Memorial Sloan Kettering Cancer Center; Advanced Laparoscopy - Memorial Sloan Kettering Cancer Center
I am a board-certified surgeon who specializes in caring for patients with genitourinary cancers, including cancers of the prostate, kidney, bladder, and adrenal glands. I have been practicing at MSK for more than 13 years. My primary focus is on the use and development of innovative minimally invasive surgical techniques — such as laparoscopy, robot-assisted laparoscopy, and image-guided therapies — to treat genitourinary cancers.
I am committed to offering all my patients personalized care with the objective of providing the right treatment for the right cancer in the right patient at the right time.
To achieve this goal in prostate cancer, I use modern risk-assessment tools such as nomograms; multiparametric MRI, which evaluates the extent of disease; repeat biopsies; and highly sophisticated genomic testing of tumors. In addition, I strive to provide the best outcome for each one of my patients through careful surgical planning, meticulous surgical technique, and selective use of multimodality therapy.
I work closely with my colleagues in medical and radiation oncology to determine the best approach for men with high-risk prostate cancer who have metastases to the lymph nodes.
In men with low-risk prostate cancer, I often recommend active surveillance (also known as watchful waiting) to avoid unnecessary treatment and to help patients enjoy their quality of life to the fullest extent possible.
I perform approximately four to six prostate cancer surgeries a week and about 150 to 200 each year. I’m an expert in laparoscopic and robot-assisted nerve-sparing radical prostatectomy with thorough pelvic lymph node dissection. I also have vast experience in laparoscopic and robot-assisted salvage radical prostatectomies for men whose cancer has recurred after initial radiation therapy.
For the treatment of kidney cancer — and in partnership with my patients — I use a risk/benefit strategy based on state-of-the-art imaging, predictive modeling and, when appropriate, needle biopsy data to determine the optimal management of their disease. Treatment options we consider include active surveillance; ablative therapies in which extreme cold or heat are used to destroy a tumor; partial nephrectomy, meaning that only the part of the kidney with cancer is removed, leaving as much healthy kidney as possible; or radical nephrectomy, in which the entire kidney is removed.
Minimally invasive partial nephrectomy represents close to 90 percent of the kidney surgeries I perform. To do these surgeries successfully, I have developed with my colleagues at MSK a novel anatomical risk assessment tool to help inform patients about the complexity of the procedure and provide surgeons with a roadmap for the actual operation itself.
My clinical research focuses on improving surgical quality and introducing new techniques to improve both the performance and outcomes of surgery. From a translational research perspective, I’ve been actively working with my colleagues on MSK’s Nuclear Medicine Service and in our Nanotechnology Center to develop novel molecular imaging tracers that can visualize and distinguish cancer cells from normal cells. This is an important step forward in allowing surgeons to see microscopic deposits of cancer cells and ensure their complete removal during surgery. We’re currently conducting two clinical trials of this exciting new technique.
I am a member of the Society of Urologic Oncology, the American Urological Association, the European Association of Urology, and other national and international societies. I teach advanced laparoscopic and robotic surgery to members of the European Association of Urology and the American Association of Urology. In addition, I serve on the editorial board and as a reviewer for a number of peer-reviewed urology and cancer journals and lecture internationally on the role of minimally invasive surgery in the treatment of prostate and kidney cancers.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Touijer’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Karim A. Touijer discloses the following relationships and financial interests:
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.